IHC-P, IF-IC, FC-FP
H M Mk
Endogenous
Rabbit IgG
#Q9BYW2
29072
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Immunohistochemistry (Paraffin) | 1:300 - 1:1200 |
| Immunofluorescence (Immunocytochemistry) | 1:1000 - 1:4000 |
| Flow Cytometry (Fixed/Permeabilized) | 1:400 - 1:1600 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the carboxy terminus of human SETD2 protein.
Background
SET domain-containing protein 2 (SETD2 or SET2), also known as lysine N-methyltransferase 3 A (KMT3A), huntingtin yeast partner B (HYBP), and huntingtin-interacting factor (HIF-1), is a ubiquitously expressed nuclear protein methyltransferase that is responsible for the majority of tri-methylation of histone H3 on lysine 36 (H3K36Me3) (1-3). SETD2-mediated H3K36Me3 is critical for proper regulation of transcription elongation, RNA splicing and DNA mismatch repair (1). SETD2 interacts with RNA polymerase II (RNAPII) that is hyper-phosphorylated on the C-terminal domain (CTD) of the largest subunit Rpb1 (2-4). Upon hyper-phosphorylation of the RNAPII CTD during activation of transcriptional elongation, SETD2 is recruited and facilitates tri-methylation of histone H3 lysine 36 in the body of transcriptionally active genes (2-4). H3K36Me3 then acts to recruit the transcription elongation factor FACT, which modulates nucleosome dynamics to facilitate transcription elongation and prevent cryptic transcriptional initiation (5). In addition, H3K36Me3 acts to recruit RNA-splicing proteins and regulate proper splicing of introns concurrent with transcriptional elongation (3, 6-9). In addition to regulating transcription, SETD2-dependent H3K36Me3 regulates DNA mismatch repair by recruiting MutSα (MSH2 and MSH6) to chromatin during G1 and early S phase (10). Loss of SETD2 results in an increase in microsatellite instability and elevated levels of spontaneous mutations (10). SETD2 is often mutated and/or inactivated in multiple types of cancer, including renal cell carcinoma, leukemia, melanoma and liver cancer (11-13).
- Wagner, E.J. and Carpenter, P.B. (2012) Nat Rev Mol Cell Biol 13, 115-26.
- Sun, X.J. et al. (2005) J Biol Chem 280, 35261-71.
- Edmunds, J.W. et al. (2008) EMBO J 27, 406-20.
- Yoh, S.M. et al. (2008) Genes Dev 22, 3422-34.
- Carvalho, S. et al. (2013) Nucleic Acids Res 41, 2881-93.
- Kolasinska-Zwierz, P. et al. (2009) Nat Genet 41, 376-81.
- Luco, R.F. et al. (2010) Science 327, 996-1000.
- Pradeepa, M.M. et al. (2012) PLoS Genet 8, e1002717.
- de Almeida, S.F. et al. (2011) Nat Struct Mol Biol 18, 977-83.
- Li, F. et al. (2013) Cell 153, 590-600.
- Liao, L. et al. (2015) Cancer Genet 208, 206-14.
- Chopra, M. and Bohlander, S.K. (2015) Cancer Genet 208, 192-205.
- Kudithipudi, S. and Jeltsch, A. (2014) Biochim Biophys Acta 1846, 366-79.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Applications Key
IHC-P: Immunohistochemistry (Paraffin) IF-IC: Immunofluorescence (Immunocytochemistry) FC-FP: Flow Cytometry (Fixed/Permeabilized)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.